ZDA
HRTX icon

Zweig-DiMenna Associates’s Heron Therapeutics HRTX Stock Holding History

Zweig-DiMenna Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-128,592
Closed -$197K – 87
2024
Q4 		$197K Hold
128,592
– – 0.01% 89
2024
Q3 		$256K Hold
128,592
– – 0.03% 85
2024
Q2 		$450K Sell
128,592
-191,538
-60% -$588K 0.05% 72
2024
Q1 		$887K Hold
320,130
– – 0.08% 110
2023
Q4 		$544K Hold
320,130
– – 0.06% 100
2023
Q3 		$330K Hold
320,130
– – 0.04% 108
2023
Q2 		$371K Buy
320,130
+198,500
+163% +$354K 0.05% 110
2023
Q1 		$184K Sell
121,630
-19,220
-14% -$48.1K 0.02% 104
2022
Q4 		$352K Hold
140,850
– – 0.05% 103
2022
Q3 		$594K Buy
140,850
+89,350
+173% +$350K 0.13% 78
2022
Q2 		$144K Hold
51,500
– – 0.03% 89
2022
Q1 		$295K Buy
+51,500
New +$377K 0.04% 96

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zweig-DiMenna Associates's HRTX Position: Q1 2025 in Review

Zweig-DiMenna Associates sold out of Heron Therapeutics (HRTX) in Q1 2025, closing a stake of 128,592 shares — an estimated $197K sold.

Zweig-DiMenna Associates first reported a position in HRTX in Q1 2022 and held it in 12 quarters. The position peaked at $887K in Q1 2024. 164 funds tracked by Wall St. Rank hold HRTX as of Q1 2025.

  • Zweig-DiMenna Associates reported no remaining Heron Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 128,592 Heron Therapeutics shares in Q1 2025, an estimated $197K.
  • Zweig-DiMenna Associates first reported a position in Heron Therapeutics in Q1 2022 and held it in 12 quarters.
  • Zweig-DiMenna Associates's Heron Therapeutics position peaked at $887K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2025.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2025, filed 7 May 2025.